Canada’s Prince Edward Island (PEI) becomes the 11th Canadian jurisdiction to announce the adoption of biosimilars switching policies.
PEI follows in the footsteps of those who have already adopted such policies, British Columbia (May 2019) [1], Alberta (December 2019) [2], New Brunswick (April 2021) [3], Quebec (July 2021) [4], the Northwest Territories (December 2021) [5], Nova Scotia (February 2022) [6], Saskatchewan (October 2022) [7], Ontario (December 2022) [8], Newfoundland and Labrador, and Yukon (May 2023) [9]. Now, only Manitoba and Nunavut remain as jurisdictions in Canada without a biosimilar transition policy. However, Nunavut is a jurisdiction that does not have a public health plan.
As part of the policy, patients enrolled in the PEI Pharmacare programme who are taking certain reference biologicals will be required to transition to a biosimilar version, see Table 1. Additionally, all new patients in need of therapy using the reference biologicals will be required to start on a biosimilar. Patients have been advised that if they are taking any of the specified reference products they will need to switch to the biosimilar version by 30 June 2024.
Table 1: Reference biologics subject to PEI's adopted biosimilars switching policy
| Drug
|
Originator brand name (switch from)
|
Biosimilar brand name (switch to)
|
Reimbursed conditions may include
|
| Insulin aspart
|
NovoRapid®
|
Kirsty®
Trurapi®
|
Diabetes
|
| Insulin glargine
|
Lantus®
|
Basaglar®
Semglee®™
|
Diabetes
|
| Insulin lispro
|
Humalog®
|
Admelog®
|
Diabetes
|
| Adalimumab
|
Humira®
|
Abrilada®
Amgevita®
Hadlima®
Hulio®
Hyrimoz®
Idacio®
Simlandi™
Yuflyma™
|
Ankylosing spondylitis
Crohn's disease
Hidradenitis suppurativa
Juvenile idiopathic arthritis
Plaque psoriasis
Psoriatic arthritis
Rheumatoid arthritis
Ulcerative colitis
Uveitis
|
| Etanercept
|
Enbrel®
|
Brenzys®
Erelzi®
|
Ankylosing spondylitis
Juvenile idiopathic arthritis
Plaque psoriasis
Psoriatic arthritis
Rheumatoid arthritis
|
Glatiramer acetate
(a non-biologic complex drug)
|
Copaxone®
|
Glatect™
|
Multiple sclerosis
|
| Infliximab
|
Remicade®
|
Inflectra®
Renflexis®
|
Ankylosing spondylitis
Crohn’s disease
Plaque psoriasis
Psoriatic arthritis
Rheumatoid arthritis
Ulcerative colitis
|
| Rituximab
|
Rituxan®
|
Riabni™
Riximyo®
Ruxience™
Truxima
|
Granulomatosis with polyangiitis (GPA)
Microscopic polyangiitis (MPA)
Rheumatoid Arthritis
|
Source: PEI Biosimilar Initiative | Government of Prince Edward Island
'This switch will allow PEI to optimize the use of public resources, invest more in new and innovative therapies and continue to grow the list of publicly funded medications while improving access and affordability for all Islanders’, said Kilby Rinco, Health PEI Director of Provincial Pharmacy Services, PD&T Co-Chair. ‘Patients and healthcare providers can be confident that the quality, safety and patient benefits of biosimilars are highly similar to the original biologicaldrugs based on the Health Canada framework.’
Related articles
Law and ethics of switching to biosimilars in Canada
Praise for Canada’s BC after it adopts biosimilar transitioning policy
|
LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View the latest headline article: Avances en la disponibilidad de medicamentos innovadores en México Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Ver el último artículo de cabecera: Avances en la disponibilidad de medicamentos innovadores en México !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
|
References
1. GaBI Online - Generics and Biosimilars Initiative. Canada’s British Columbia to switch patients to biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Nov 7]. Available from:
www.gabionline.net/policies-legislation/Canada-s-British-Columbia-to-switch-patients-to-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. Concerns raised as Canada’s Alberta plans to switch patients to biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Nov 7]. Available from:
www.gabionline.net/Policies-Legislation/Concerns-raised-as-Canada-s-Alberta-plans-to-switch-patients-to-biosimilars
3. GaBI Online - Generics and Biosimilars Initiative. Concerns over Canada’s New Brunswick transition to biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Nov 7]. Available from:
www.gabionline.net/biosimilars/general/concerns-over-canada-s-new-brunswick-transition-to-biosimilars
4. GaBI Online - Generics and Biosimilars Initiative. Quebec announces biosimilar switching policy [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Nov 7]. Available from:
www.gabionline.net/biosimilars/general/quebec-announces-biosimilar-switching-policy
5. GaBI Online - Generics and Biosimilars Initiative. Northwest territories Canada announces biosimilars switching policy [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Nov 7]. Available from:
www.gabionline.net/biosimilars/general/northwest-territories-canada-announces-biosimilars-switching-policy
6. GaBI Online - Generics and Biosimilars Initiative. Nova Scotia Canada implements biosimilar switching policy [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Nov 7]. Available from:
www.gabionline.net/biosimilars/general/nova-scotia-canada-implements-biosimilar-switching-policy
7. GaBI Online - Generics and Biosimilars Initiative. Canada’s Saskatchewan province introduces biosimilars switching policy [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Nov 7]. Available from:
www.gabionline.net/biosimilars/general/canada-s-saskatchewan-province-introduces-biosimilars-switching-policy
8. GaBI Online - Generics and Biosimilars Initiative. Ontario becomes third Canadian province to switch patients to biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Nov 7]. Available from:
www.gabionline.net/biosimilars/general/Ontario-becomes-third-Canadian-province-to-switch-patients-to-biosimilars
9. GaBI Online - Generics and Biosimilars Initiative. Biosimilars switching policies for Canada’s Newfoundland and Labrador, and Yukon [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Nov 7]. Available from: www.gabionline.net/biosimilars/general/biosimilars-switching-policies-for-canada-s-newfoundland-and-labrador-and-yukon
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment